relay therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. by placing protein motion at the heart of drug discovery, relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. headquartered in cambridge, mass., relay therapeutics is a private company launched in 2016. to date, relay therapeutics has raised $120m in financing from third rock ventures, bvf partners, gv (formerly google ventures), an affiliate of d.e. shaw research, casdin capital, ecor1 capital, section 32 and alexandria venture investments. our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. if you're creative, collaborative and passionate
![Relay Therapeutics logo](/files/LOGO/1812364-RLAY.png)
Company profile
Ticker
RLAY
Exchange
Website
CEO
Sanjiv K. Patel
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Relay Securities Corporation • Relay ML Discovery, LLC ...
RLAY stock data
Latest filings (excl ownership)
8-K
Termination of a Material Definitive Agreement
16 Jul 24
8-K
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
6 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
3 Jun 24
10-Q
2024 Q1
Quarterly report
2 May 24
8-K
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
2 May 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
S-8
Registration of securities for employees
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
Latest ownership filings
144
Notice of proposed sale of securities
26 Jul 24
144
Notice of proposed sale of securities
25 Jul 24
4
Sanjiv Patel
1 Jul 24
4
Donald A Bergstrom
1 Jul 24
4
Peter Rahmer
1 Jul 24
4
Thomas Catinazzo
1 Jul 24
4
Brian Adams
1 Jul 24
144
Notice of proposed sale of securities
27 Jun 24
4
Jami Rubin
12 Jun 24
4
Mark Murcko
5 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 155.57 mm | 155.57 mm | 155.57 mm | 155.57 mm | 155.57 mm | 155.57 mm |
Cash burn (monthly) | (no burn) | 690.00 k | 30.12 mm | 30.18 mm | 16.77 mm | 23.63 mm |
Cash used (since last report) | n/a | 2.67 mm | 116.46 mm | 116.70 mm | 64.86 mm | 91.35 mm |
Cash remaining | n/a | 152.91 mm | 39.11 mm | 38.88 mm | 90.72 mm | 64.23 mm |
Runway (months of cash) | n/a | 221.6 | 1.3 | 1.3 | 5.4 | 2.7 |
Institutional ownership, Q1 2024
96.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 181 |
Opened positions | 74 |
Closed positions | 13 |
Increased positions | 49 |
Reduced positions | 35 |
13F shares | Current |
---|---|
Total value | 987.07 bn |
Total shares | 127.51 mm |
Total puts | 1.70 k |
Total calls | 4.20 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
SB Investment Advisers | 27.90 mm | $231.61 bn |
Vanguard | 11.82 mm | $98.07 bn |
BLK Blackrock | 9.80 mm | $81.31 bn |
Casdin Capital | 7.42 mm | $61.62 bn |
T. Rowe Price | 6.88 mm | $57.10 mm |
STT State Street | 6.02 mm | $49.97 bn |
BLVGF Bellevue | 5.93 mm | $49.19 bn |
ArrowMark Colorado | 4.01 mm | $33.24 bn |
Nextech Invest | 3.85 mm | $31.93 bn |
Braidwell | 3.74 mm | $31.08 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Jun 24 | Sanjiv Patel | Common Stock | Grant | Acquire A | No | No | 5.54 | 2,108 | 11.68 k | 766,130 |
30 Jun 24 | Peter Rahmer | Common Stock | Grant | Acquire A | No | No | 5.54 | 2,108 | 11.68 k | 434,288 |
27 Jun 24 | Adams Brian | Common Stock | Sell | Dispose S | No | No | 6.26 | 295 | 1.85 k | 325,472 |
27 Jun 24 | Thomas Catinazzo | Common Stock | Sell | Dispose S | No | Yes | 6.24 | 9,078 | 56.65 k | 330,430 |
27 Jun 24 | Thomas Catinazzo | Common Stock | Sell | Dispose S | No | No | 6.26 | 295 | 1.85 k | 339,508 |
27 Jun 24 | Peter Rahmer | Common Stock | Sell | Dispose S | No | No | 6.26 | 245 | 1.53 k | 432,180 |
27 Jun 24 | Bergstrom Donald A | Common Stock | Sell | Dispose S | No | No | 6.26 | 648 | 4.06 k | 526,779 |
News
Barclays Maintains Overweight on Relay Therapeutics, Lowers Price Target to $14
26 Jul 24
JMP Securities Maintains Market Outperform on Relay Therapeutics, Lowers Price Target to $21
18 Jul 24
Expert Ratings For Relay Therapeutics
17 Jul 24
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $18
17 Jul 24
Relay Therapeutics Receives Notice Of Termination From Genentech For Collaboration And License Agreement; Relay Received $121.8M From Genentech, Including $75M Upfront And $45M In Milestones
16 Jul 24
Press releases
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
5 Jun 24
Relay Therapeutics to Participate in Upcoming Investor Conferences
21 May 24
Treatment AI's (CSE: TRUE) New Developments Promise Significant Advancements in Medical Education
15 May 24
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
13 May 24
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
2 May 24